BCMA-Targeted Treatments in Multiple Myeloma: Novel Approaches and Recent Advances

BCMA-Targeted Treatments in Multiple Myeloma: Novel Approaches and Recent Advances is organized by Pharmacy Times Continuing Education (PTCE).,Release date: August 8, 2022,Expiration date: August 8, 2023,Description:,B-cell maturation antigen (BCMA) is overexpressed in multiple myeloma (MM) and has emerged as a viable therapeutic target. With multiple BCMA-targeted constructs approved and under investigation in the MM treatment landscape, it will be important for pharmacists to identify patients with MM who are candidates for BCMA-targeted agents based on patient- and disease-related factors. Though BCMA-targeted therapies may likely improve outcomes for patients with MM, the associated resources necessary for planning, administration, monitoring, and costs present additional challenges for patients, pharmacies, and payers. This article will explore ongoing and evolving data surrounding the use of BCMA-targeted therapies in MM that managed care pharmacists can utilize to plan appropriate resources, develop eligibility criteria, and promote cost-effective treatment within their organizations.,Educational Objectives:,At the completion of this activity, participants will be able to:,• Determine the biology of B-cell maturation antigen (BCMA) in multiple myeloma (MM) and the common BCMA-targeted treatment modalities.,• Analyze the clinical data for recently approved and emerging BCMA-targeted agents in the treatment of MM.,• Explore the economic burden of MM and the cost-effective strategies for the use of BCMA-targeted therapies.